Drug Delivery

BioNxt Solutions announced its German subsidiary received an “Intention to Grant” from the European Patent Office for a sublingual cladribine thin-film patent application (no. 23 729 446.7) targeting multiple sclerosis. Coupled with an EAPO “Readiness to Grant,” the filings could protect across 54 jurisdictions, reaching nearly 1 billion people. BioNxt is pursuing filings in the US, North America, and Japan, while advancing BNT23001 through bioequivalence studies and seeking partnerships, aiming for market entry in the growing oral MS treatment market.

BioNxt Solutions (BNXTF) completed a debt settlement with an arm’s length creditor, settling a $225,010 debt via share issuance (112,505 shares at CAD$1.00) and a $112,505 cash payment. The newly issued shares are subject to a four-month and one-day holding period according to CSE policies. This move aims to strengthen financial footing while preserving cash for core operations, though it may result in minor shareholder dilution. BioNxt focuses on bioscience innovation, particularly drug delivery technologies.

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.